Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function

Molecular Pharmacology

Volumn 78, Issue 2, 2010, Pages 166-174

  Yin, Li ^a   Ahmad, Rehan ^a   Kosugi, Michio ^a   Kufe, Turner ^a   Vasir, Baldev ^a   Avigan, David ^a   Kharbanda, Surender ^b   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Genus Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CP 1 PEPTIDE; CP 2 PEPTIDE; GO 201 PEPTIDE; GO 203 PEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUCIN 1 C TERMINAL TRANSMEMBRANE SUBUNIT ONCOPROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MOUSE; MULTIPLE MYELOMA; MYELOMA; MYELOMA CELL; NONHUMAN; NUDE MOUSE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; MUCIN-1; MULTIPLE MYELOMA; NF-KAPPA B; REACTIVE OXYGEN SPECIES; TRANSPLANTATION, HETEROLOGOUS;

EID: 77954897999     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.065011     Document Type: Article

References (37)

1. Ahmad R, Raina D, Joshi MD, Kawano T, Ren J, Kharbanda S, and Kufe D (2009) MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res 69:7013-7021.
2. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S, and Kufe D (2007) MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol 9:1419-1427.
3. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115-130.
4. Baldus SE, Palmen C, and Thiele J (2007) MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma. Histol Histopathol 22:889-893. (Pubitemid 47034155)
5. Burton J, Mishina D, Cardillo T, Lew K, Rubin A, Goldenberg DM, and Gold DV (1999) Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma. Clin Cancer Res 5 (10 Suppl):3065S-3072S.
6. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, and Anderson KC (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104-1112.
7. Cloosen S, Gratama J, van Leeuwen EB, Senden-Gijsbers BL, Oving EB, von Mensdorff-Pouilly S, Tarp MA, Mandel U, Clausen H, Germeraad WT, et al. (2006) Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol 135:513-516.
8. Dutta J, Fan Y, Gupta N, Fan G, and Gélinas C (2006) Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25:6800-6816.
9. Grillot DA, González-García M, Ekhterae D, Duan L, Inohara N, Ohta S, Seldin MF, and Nuñez G (1997) Genomic organization, promoter region analysis, and chromosome localization of the mouse bcl-x gene. J Immunol 158:4750-4757.
10. Hayden MS and Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344-362.
11. Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K, Raje N, Protopopov A, Munshi NC, Richardson PG, et al. (2009) Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 113:5228-5236.
12. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647.
13. Hideshima T, Chauhan D, Schlossman R, Richardson P, and Anderson KC (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519-4527.
14. Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, et al. (2006) MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 12:5887-5894.
15. Huang L, Chen D, Liu D, Yin L, Kharbanda S, and Kufe D (2005) MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 65:10413-10422.
16. Joshi MD, Ahmad R, Yin L, Raina D, Rajabi H, Bubley G, Kharbanda S, and Kufe D (2009) MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther 8:3056-3065.
17. Jourdan M, Moreaux J, Vos JD, Hose D, Mahtouk K, Abouladze M, Robert N, Baudard M, Rème T, Romanelli A, et al. (2007) Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol 138:160-168.
18. Karin M and Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3:221-227.
19. Kawano T, Ahmad R, Nogi H, Agata N, Anderson K, and Kufe D (2008) MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. Int J Oncol 33:153-159.
20. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12:131-144.
21. Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9:874-885.
22. Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M, and Kufe D (2007) Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 282:19321-19330.
23. Li Y, Chen W, Ren J, Yu WH, Li Q, Yoshida K, and Kufe D (2003) DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7. Cancer Biol Ther 2:187-193.
24. Luo JL, Kamata H, and Karin M (2005) IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 115:2625-2632.
25. McGahon AJ, Martin SJ, Bissonnette RP, Mahboubi A, Shi Y, Mogil RJ, Nishioka WK, and Green DR (1995) The end of the (cell) line: methods for the study of apoptosis in vitro. Methods Cell Biol 46:153-185.
26. Paydaş S, Sahin B, Gönlüşen G, Hazar B, and Zorludemir S (2001) MUC1 expression in plasmacytoma. Leuk Res 25:221-225.
27. Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S, and Kufe D (2009) Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 69:5133-5141.
28. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, and Kufe D (2007) The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 27:992-1004. (Pubitemid 47488189)
29. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, and Kufe D (2004) Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5:163-175.
30. Ryan EP, Pollock SJ, Pollack SJ, Murant TI, Bernstein SH, Felgar RE, and Phipps RP (2005) Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol 174:2619-2626.
31. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, and Yachi A (1994) Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153:2102-2109. (Pubitemid 24256681)
32. Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, et al. (1999) Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 93:1287-1298.
33. Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, Anderson K, Kufe D, and Avigan D (2005) Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol 129:687-700.
34. Weinstein IB and Joe A (2008) Oncogene addiction. Cancer Res 68:3077-3080.
35. Yin L, Kharbanda S, and Kufe D (2007) Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia. J Biol Chem 282:257-266.
36. Yin L, Kharbanda S, and Kufe D (2009) MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol 34:1691-1699.
37. Yin L, Li Y, Ren J, Kuwahara H, and Kufe D (2003) Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 278:35458-35464.